Orano Med and Orbit Discovery collaborate on radioligand therapies for cancer
Both companies will work to advance the development of novel radiopharmaceuticals
Read MoreBoth companies will work to advance the development of novel radiopharmaceuticals
Read MoreThe platform will be used to advance the effectiveness of antibiotics
Read MoreImmunoGen is expected to receive an upfront payment from Takeda plus additional payment
Read MoreThe ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme
Read MoreThe decision follows a recent recommendation from the European Medicines Agency’s human medicines committee
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
